Enteric-Coated Strategies in Colorectal Cancer Nanoparticle Drug Delivery System

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2020 Oct 29

PMID 33116423

Citations 15

Authors

Nasrul Wathoni

An Ny Nguyen

Agus Rusdin

Abd Kakhar Umar

Ahmed Fouad Abdelwahab Mohammed

Keiichi Motoyama

I Made Joni

Muchtaridi Muchtaridi

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the most common cancer diseases with the increase of cases prevalence >5% every year. Multidrug resistance mechanisms and non-localized therapy become primary problems of chemotherapy drugs for curing colorectal cancer disease. Therefore, the enteric-coated nanoparticle system has been studied and proved to be able to resolve those problems with good performance for colorectal cancer. The highlight of our review aims to summarize and discuss the enteric-coated nanoparticle drug delivery system specific for colorectal cancer disease. The main and supporting literatures were collected from published research articles of journals indexed in Scopus and PubMed databases. In the oral route of administration, Eudragit pH-sensitive copolymer as a coating agent prevents the degradation of the nanoparticle system from the gastric fluid and releases drug to intestinal-colon track. Therefore, it provides a colon-specific targeting ability. Impressively, enteric-coated nanoparticles having a sustained release profile significantly increase the cytotoxic effect of chemotherapeutic drugs and achieve cell-specific target delivery. The enteric-coated nanoparticle drug delivery system represents an excellent modification to improve the effectiveness and performance of anticancer drugs for colorectal cancer disease in terms of the oral route of administration.

Citing Articles

A Comprehensive Review of Challenges in Oral Drug Delivery Systems and Recent Advancements in Innovative Design Strategies.

Loke Y, Jayakrishnan A, Mod Razif M, Yee K, Kee P, Goh B Curr Pharm Des. 2024; 31(5):360-376.

PMID: 39390835 DOI: 10.2174/0113816128338560240923073357.

Advancements in Colon-Targeted Drug Delivery: A Comprehensive Review on Recent Techniques with Emphasis on Hot-Melt Extrusion and 3D Printing Technologies.

Alshammari N, Elkanayati R, Vemula S, Al Shawakri E, Uttreja P, Almutairi M AAPS PharmSciTech. 2024; 25(7):236.

PMID: 39379609 DOI: 10.1208/s12249-024-02965-w.

Enteral Route Nanomedicine for Cancer Therapy.

Zhang L, Du R, Wang D, Qin J, Yu C, Zhang L Int J Nanomedicine. 2024; 19:9889-9919.

PMID: 39351000 PMC: 11439897. DOI: 10.2147/IJN.S482329.

The Exploitation of pH-Responsive Eudragit-Coated Mesoporous Silica Nanostructures in the Repurposing of Terbinafine Hydrochloride for Targeted Colon Cancer Inhibition: Design Optimization, In Vitro Characterization, and Cytotoxicity Assessment.

Alyami M, Musallam A, Ibrahim T, Mahdy M, Elnahas H, Aldeeb R Pharmaceutics. 2023; 15(12).

PMID: 38140018 PMC: 10747614. DOI: 10.3390/pharmaceutics15122677.

Redox/pH-responsive hollow manganese dioxide nanoparticles for thyroid cancer treatment.

Liu J, Guo C, Li C, Jia Q, Xie Z, Wang Z Front Chem. 2023; 11:1249472.

PMID: 37780983 PMC: 10540626. DOI: 10.3389/fchem.2023.1249472.

References

He H, Zhang X, Sheng Y . Enteric-coated capsule containing β-galactosidase-loaded polylactic acid nanocapsules: enzyme stability and milk lactose hydrolysis under simulated gastrointestinal conditions. J Dairy Res. 2014; 81(4):479-84. DOI: 10.1017/S0022029914000491. View

Chen S, Guo F, Deng T, Zhu S, Liu W, Zhong H . Eudragit S100-Coated Chitosan Nanoparticles Co-loading Tat for Enhanced Oral Colon Absorption of Insulin. AAPS PharmSciTech. 2016; 18(4):1277-1287. DOI: 10.1208/s12249-016-0594-z. View

Birgisson H, Pahlman L, Gunnarsson U, Glimelius B . Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol. 2007; 46(4):504-16. DOI: 10.1080/02841860701348670. View

Li C, Zhou K, Chen D, Xu W, Tao Y, Pan Y . Solid lipid nanoparticles with enteric coating for improving stability, palatability, and oral bioavailability of enrofloxacin. Int J Nanomedicine. 2019; 14:1619-1631. PMC: 6402439. DOI: 10.2147/IJN.S183479. View

Luo S, Hao J, Gao Y, Liu D, Cai Q, Yang X . Pore size effect on adsorption and release of metoprolol tartrate in mesoporous silica: Experimental and molecular simulation studies. Mater Sci Eng C Mater Biol Appl. 2019; 100:789-797. DOI: 10.1016/j.msec.2019.03.050. View

Jain A, Jain S, Jain R, Kohli D . Coated chitosan nanoparticles encapsulating caspase 3 activator for effective treatment of colorectral cancer. Drug Deliv Transl Res. 2015; 5(6):596-610. DOI: 10.1007/s13346-015-0255-x. View

Kirchhoff P, Clavien P, Hahnloser D . Complications in colorectal surgery: risk factors and preventive strategies. Patient Saf Surg. 2010; 4(1):5. PMC: 2852382. DOI: 10.1186/1754-9493-4-5. View

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

Nguyen D, Clasen C, Van den Mooter G . Encapsulating darunavir nanocrystals within Eudragit L100 using coaxial electrospraying. Eur J Pharm Biopharm. 2016; 113:50-59. DOI: 10.1016/j.ejpb.2016.12.002. View

10.

Muller C, Perera G, Konig V, Bernkop-Schnurch A . Development and in vivo evaluation of papain-functionalized nanoparticles. Eur J Pharm Biopharm. 2013; 87(1):125-31. DOI: 10.1016/j.ejpb.2013.12.012. View

11.

Sykes E, Chen J, Zheng G, Chan W . Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014; 8(6):5696-706. DOI: 10.1021/nn500299p. View

12.

Thakral S, Thakral N, Majumdar D . Eudragit: a technology evaluation. Expert Opin Drug Deliv. 2012; 10(1):131-49. DOI: 10.1517/17425247.2013.736962. View

13.

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

14.

Yu F, Li Y, Liu C, Chen Q, Wang G, Guo W . Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin. Int J Pharm. 2015; 484(1-2):181-91. DOI: 10.1016/j.ijpharm.2015.02.055. View

15.

Luqmani Y . Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005; 14 Suppl 1:35-48. DOI: 10.1159/000086183. View

16.

Choi Y, Han H . Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig. 2018; 48(1):43-60. PMC: 6244736. DOI: 10.1007/s40005-017-0370-4. View

17.

Dadwal A, Baldi A, Narang R . Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):295-305. DOI: 10.1080/21691401.2018.1457039. View

18.

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

19.

Rajpoot K, Jain S . Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach. Int J Biol Macromol. 2020; 151:830-844. DOI: 10.1016/j.ijbiomac.2020.02.132. View

20.

Ma Y, Fuchs A, Boase N, Rolfe B, Coombes A, Thurecht K . The in vivo fate of nanoparticles and nanoparticle-loaded microcapsules after oral administration in mice: Evaluation of their potential for colon-specific delivery. Eur J Pharm Biopharm. 2015; 94:393-403. DOI: 10.1016/j.ejpb.2015.06.014. View